Repurposing of LSD — a scoping review of current clinical trials

LSD was banned in many countries for a very long time and was purchased by users for recreational use on the black market. Since 2014, there has been steady growth in interest in its potential use in treating pain disorders and neuropsychiatric conditions. Consequently, an increasing number of studies on the repurposing of LSD have been conducted; in some cases, the conditions treated corresponded to those in studies from the 1950s and 1960s, while in others, the scope was expanded to include new areas of application. Clinicaltrials.org, ANZCTR, the Netherlands trial registry and PubMed research were used to identify the clinical trials. For this publication, 51 studies were analyzed, 25 of which were published. The goal is to map the status quo of the current state of research and analyze the study design. The analysis parameters included study design, conditions, sponsoring, study location, and overall outcome. Most studies are still in phase 1, followed by phase 2. Three phase 3 studies are currently being conducted. The condition entities were: alcohol use disorder ( n = 1), anxiety disorders ( n = 3), Attention-Deficit/Hyperactivity Disorder (ADHD) ( n = 1), cluster headache (chronic and non-chronic, n = 2); major depressive disorder ( n = 4), premenstrual disorders (premenstrual syndrome (PMS)) and Premenstrual Dysphoric Disorder (PMDD) ( n = 1), palliative care/end-of-life distress ( n = 2). The most used dosage is 100 µg. Most studies are interventional RCTs using inactive placebos and are conducted in Switzerland, followed by the USA, the Netherlands, and New Zealand/Australia. The outcome of the published trials was analyzed further. So far, LSD shows possible benefits in the treatment of anxiety disorders and major depressive disorders. The effectiveness of microdosing could not be adequately proven, and the results varied greatly, which could be due to differences in dosage and administration. More detailed studies, particularly phase 2 or phase 3 studies, are needed to make more informed statements.

Authors

Publication Details

Journal
Naunyn-Schmiedeberg s Archives of Pharmacology
Published
2026-11-20
DOI
https://doi.org/10.1007/s00210-026-06103-0
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Repurposing of LSD — a scoping review of current clinical trials

Roland Seifert, Lara Marie Ziegler
Naunyn-Schmiedeberg s Archives of Pharmacology
Psychedelics and Drug Studies
article

Repurposing of LSD — a scoping review of current clinical trials

Roland Seifert, Lara Marie Ziegler
article en

Abstract

LSD was banned in many countries for a very long time and was purchased by users for recreational use on the black market. Since 2014, there has been steady growth in interest in its potential use in treating pain disorders and neuropsychiatric conditions. Consequently, an increasing number of studies on the repurposing of LSD have been conducted; in some cases, the conditions treated corresponded to those in studies from the 1950s and 1960s, while in others, the scope was expanded to include new areas of application. Clinicaltrials.org, ANZCTR, the Netherlands trial registry and PubMed research were used to identify the clinical trials. For this publication, 51 studies were analyzed, 25 of which were published. The goal is to map the status quo of the current state of research and analyze the study design. The analysis parameters included study design, conditions, sponsoring, study location, and overall outcome. Most studies are still in phase 1, followed by phase 2. Three phase 3 studies are currently being conducted. The condition entities were: alcohol use disorder ( n = 1), anxiety disorders ( n = 3), Attention-Deficit/Hyperactivity Disorder (ADHD) ( n = 1), cluster headache (chronic and non-chronic, n = 2); major depressive disorder ( n = 4), premenstrual disorders (premenstrual syndrome (PMS)) and Premenstrual Dysphoric Disorder (PMDD) ( n = 1), palliative care/end-of-life distress ( n = 2). The most used dosage is 100 µg. Most studies are interventional RCTs using inactive placebos and are conducted in Switzerland, followed by the USA, the Netherlands, and New Zealand/Australia. The outcome of the published trials was analyzed further. So far, LSD shows possible benefits in the treatment of anxiety disorders and major depressive disorders. The effectiveness of microdosing could not be adequately proven, and the results varied greatly, which could be due to differences in dosage and administration. More detailed studies, particularly phase 2 or phase 3 studies, are needed to make more informed statements.

Naunyn-Schmiedeberg s Archives of Pharmacology
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon